$INCY

Issa Mohamed Khairie sold $126K of INCY

Issa Mohamed Khairie (EVP, Head of U.S. Commercial) sold 1,093 shares of INCYTE CORP (INCY) at $115.01 ($0.13M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Issa Mohamed Khairie
Published Jul 20, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosure updates insider trading records but does not introduce new information about Incyte’s business performance or outlook.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure reduces interpretive weight.

03

What to watch

The article does not state whether other insiders sold/bought around the same period, nor does it quantify total insider activity beyond this one transaction.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-20 after-hours, covering a sale dated 2026-07-16

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an EVP in the U.S. Commercial organization.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows EVP Issa Mohamed Khairie sold 1,093 shares on 2026-07-16 under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale with a stated 10b5-1 plan, and it provides no new company fundamentals, guidance, or regulatory/contract developments.

Market effects

No direct read-through to biotech sector fundamentals from a single 10b5-1 insider sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • INCY

    Incyte Corporation, the company whose insider transaction is disclosed.

  • Issa Mohamed Khairie

    EVP, Head of U.S. Commercial, who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

$INCYHighAI 8/10

Incyte Stock: Is Wall Street Bullish or Bearish?

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.